Skip to main content
Pfizer COVID-19 vaccine appointments are available to our patients.
Sign up for Connect today
to schedule your vaccination.
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Joint Clinical Trials Office
Explore this Website
Home
About
Toggle About menu options
News
JCTO Contacts
Careers
Our Clinical Trial Locations
Partner with the JCTO
Toggle Partner with the JCTO menu options
JCTO Fees
Open Clinical Trials
Investigators
Patients
Toggle Patients menu options
What is a Clinical Trial?
Frequently Asked Questions
Clinical Trial Questions to Ask Your Healthcare Team
Clinical Trials: Common Terms to Know
Understanding Clinical Trials and How They Work
Understanding Clinical Trials - In Spanish | En Español
Weill Cornell Medicine
Care
Discover
Teach
Home
About
Open Clinical Trials
Investigators
Patients
Home
Clinical Trials
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
Study Status:
Open to Enrollment
Primary Investigator:
Date:
June 12, 2023
A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine With or Without Botensilimab (AGEN1181) in Patients With Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX)
Study Status:
Open to Enrollment
Primary Investigator:
Date:
June 13, 2023
A Phase 3 Randomized Study Comparing VRd Therapy followed by Ciltacabtagene Autoleucel, a CAR-T Therapy Directed Against BCMA vs VRd followed by Lenalidomide & Dexamethasone Therapy in Newly Diagnosed Multiple Myeloma for Whom HSTC is Not Planned
Study Status:
Open to Enrollment
Primary Investigator:
Date:
June 13, 2023
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)
Study Status:
Open to Enrollment
Primary Investigator:
Date:
June 13, 2023
Phase II Multicenter Trial of Iberdomide as Maintenance Therapy for Multiple Myeloma Patients with Sub Optimal Response After Autologous Hematopoietic Stem Cell Transplant (AHCT)
Study Status:
Open to Enrollment
Primary Investigator:
Date:
June 14, 2023
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL [APOLLO])
Study Status:
Open to Enrollment
Primary Investigator:
Date:
June 14, 2023
C-800-25: A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) for the Treatment of Advanced, Refractory Microsatellite Stable Colorectal Cancer Without Liver Metastases
Study Status:
Open to Enrollment
Primary Investigator:
Date:
June 14, 2023
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-Expressing Metastatic Castrate Resistant Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date:
July 12, 2023
A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination with Enzalutamide (Xtandi) in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study Status:
Open to Enrollment
Primary Investigator:
Date:
July 14, 2023
Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality: A Precision Imaging Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date:
July 17, 2023
« first
‹ previous
…
15
16
17
18
19
(current)
20
21
22
23
…
next ›
last »